Hydroxyurea Dosing in Polycythemia Vera
Start hydroxyurea at 15-20 mg/kg/day (or approximately 1000-1500 mg/day for average-sized adults), with initial control typically achieved within 12 weeks, followed by dose adjustment to maintain hematocrit <45% and platelet count <400 × 10⁹/L.
Initial Dosing Strategy
The evidence supports a conservative initial approach:
- Starting dose: 15-20 mg/kg/day 1
- For average adults (70 kg), this translates to approximately 1000-1500 mg daily
- Avoid the previously used loading dose of 30 mg/kg/day, as cytopenia typically occurs within the first 8 weeks and is more common with aggressive initial dosing 1
Dose Titration and Monitoring
Target response parameters:
- Hematocrit <45% without phlebotomy
- Platelet count <400 × 10⁹/L
- WBC count <10 × 10⁹/L
- Resolution of disease-related symptoms 2
Timeline expectations:
- Initial control achieved in >80% of patients within 12 weeks 1
- Monitor blood counts frequently during the first 8 weeks when cytopenia risk is highest
- Adjust dose based on blood count response and tolerance
Maintenance Dosing
Once initial control is achieved:
- Reduce to the lowest effective maintenance dose (often 500-1000 mg/day)
- Continue monitoring to maintain target parameters
- Average maintenance dose in clinical practice is approximately 0.72 grams (720 mg) daily 3
Special Populations
Renal impairment:
- Reduce dose by 50% in patients with creatinine clearance <60 mL/min 4
Elderly patients:
- Use lower starting doses and monitor renal function closely 4
Resistance/Intolerance Criteria
Hydroxyurea resistance is defined as 2:
- Need for phlebotomy to keep hematocrit <45% after 3 months of **at least 2 g/day** (2.5 g/day if body weight >80 kg)
- Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months of at least 2 g/day
- Failure to reduce massive splenomegaly by >50% after 3 months of at least 2 g/day
- Cytopenia at lowest dose needed for response (ANC <1.0 × 10⁹/L, platelets <100 × 10⁹/L, or Hgb <10 g/dL)
- Unacceptable toxicities (leg ulcers, mucocutaneous manifestations, GI symptoms)
Critical Caveats
Age considerations:
- Use hydroxyurea with caution in young patients (<40 years) due to potential long-term leukemogenic risk 5, 2
- Consider interferon-alpha as first-line in younger patients requiring cytoreduction 5
Common pitfall: Real-world data shows that 40% of patients on hydroxyurea still have hematocrit ≥45% at follow-up, indicating inadequate dosing or poor adherence 6. Don't accept suboptimal control—titrate the dose appropriately or switch therapy.
Leukemic transformation risk: Approximately 10% at 13 years, though this may reflect disease natural history rather than drug effect alone 7. The risk appears similar to other cytoreductive agents but remains a concern for long-term use.
Maximum dose threshold: If adequate control is not achieved with 2-2.5 g/day after 3 months, the patient meets resistance criteria and should be switched to second-line therapy (ruxolitinib or interferon-alpha) rather than continuing to escalate hydroxyurea 5, 2.